UZ Leuven

Recently closed projects/recent gesloten projecten/projets récemment fermés/kürzlich geschlossene Projekte

Phase II study with Doxorubicin/AMG655 vs Doxorubicin/Placebo in patients with metastatic soft tissue sarcoma. For non-pretreated patients. Doxorubicin is classical i.v. chemotherapy; AMG655 is a TRAIL receptor 2 agonist (hmab). Study group/sponsor: Amgen.

Compassionate use of Trabectedine. Trabectedine is a marine anticancer agent. Study group/Sponsor: PharmaMar. Contact: Prof. P. Schöffski, Prof. H. Dumez

Phase II study with Eribuline in patients with advanced or metastatic soft tissue sarcoma. For patients failing 1st- or 2nd line chemotherapy (EORTC 62052). Eribuline is a Halichondrin-B-analogue. Study group/sponsor: EORTC. Contact: Prof. P. Schöffski, Prof H. Dumez.

Randomized phase III trial of Pazopanib vs placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (EORTC 62072). For patients failing up to 4 lines of previous treatment. Study group/sponsor: EORTC. Contact: Prof. P. Schöffski, Prof. H. Dumez.

Ongoing projects/lopende projecten/projets actifs/laufende Projekte

Phase III study with Doxorubicin vs. Doxorubicin/ifosfamide in patients with metastatic soft tissue sarcoma (EORTC 62012). For non-pretreated patients. Doxorubicin and ifosfamide are classical i.v. chemotherapy agents. Study group/sponsor: EORTC. Contact: Prof. P. Schöffski, Prof. H. Dumez.

Phase II study with IMC-012 in patients with sarcoma failing chemotherapy. For patients with Ewings sarcoma, peripheral neuroectodermal tumours or soft tissue sarcoma failing various lines of chemotherapy. IMC-012 is a monoclonal antibody against the insuline-like growth factor receptor I. Study group/sponsor: Imclone/INC. Contact: Prof. P. Schöffski, Prof. H. Dumez.

Planned projects/geplande projecten/projets en développement/geplante Projekte

A phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs doxorubicin plus placebo in patients with front-line mestatic soft tissue sarcoma. Study group/sponsor: Ziopharm Oncology. Contact: Prof. Dr. P. Schöffski

TRUSTS: a phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma. Study group/sponsor: EORTC, Soft Tissue and Bone Sarcoma Group, Sarcoma Alliance for Research through Collaboration. Contact: Prof. P. Schöffski

Note: patients with soft tissue sarcomas may qualify early for our phase I trials.

• Print
• Stuur door